These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 22052826)

  • 1. Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Khuri FR
    Head Neck; 2013 Mar; 35(3):443-53. PubMed ID: 22052826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
    Licitra L; Mesia R; Rivera F; Remenár É; Hitt R; Erfán J; Rottey S; Kawecki A; Zabolotnyy D; Benasso M; Störkel S; Senger S; Stroh C; Vermorken JB
    Ann Oncol; 2011 May; 22(5):1078-1087. PubMed ID: 21048039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
    Vermorken JB; Peyrade F; Krauss J; Mesía R; Remenar E; Gauler TC; Keilholz U; Delord JP; Schafhausen P; Erfán J; Brümmendorf TH; Iglesias L; Bethe U; Hicking C; Clement PM
    Ann Oncol; 2014 Mar; 25(3):682-688. PubMed ID: 24567516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
    de Mello RA; Gerós S; Alves MP; Moreira F; Avezedo I; Dinis J
    PLoS One; 2014; 9(2):e86697. PubMed ID: 24516537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.
    Frampton JE
    Drugs; 2010 Oct; 70(15):1987-2010. PubMed ID: 20883055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.
    Vermorken JB; Psyrri A; Mesía R; Peyrade F; Beier F; de Blas B; Celik I; Licitra L
    Ann Oncol; 2014 Apr; 25(4):801-807. PubMed ID: 24577117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
    Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
    J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Mesía R; Rivera F; Kawecki A; Rottey S; Hitt R; Kienzer H; Cupissol D; De Raucourt D; Benasso M; Koralewski P; Delord JP; Bokemeyer C; Curran D; Gross A; Vermorken JB
    Ann Oncol; 2010 Oct; 21(10):1967-1973. PubMed ID: 20335368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
    Bernier J
    Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.
    Péron J; Polivka V; Chabaud S; Poupart M; Ceruse P; Ramade A; Girodet D; Zrounba P; Fayette J
    BMC Cancer; 2014 Jul; 14():504. PubMed ID: 25011678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Argiris A; Kotsakis AP; Hoang T; Worden FP; Savvides P; Gibson MK; Gyanchandani R; Blumenschein GR; Chen HX; Grandis JR; Harari PM; Kies MS; Kim S
    Ann Oncol; 2013 Jan; 24(1):220-5. PubMed ID: 22898037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New approaches to enhance chemotherapy in SCCHN.
    Bourhis J
    Ann Oncol; 2005; 16 Suppl 6():vi20-vi24. PubMed ID: 15987992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Agulnik M
    Med Oncol; 2012 Dec; 29(4):2481-91. PubMed ID: 22252310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum-based chemotherapy plus cetuximab in head and neck cancer.
    Vermorken JB; Mesia R; Rivera F; Remenar E; Kawecki A; Rottey S; Erfan J; Zabolotnyy D; Kienzer HR; Cupissol D; Peyrade F; Benasso M; Vynnychenko I; De Raucourt D; Bokemeyer C; Schueler A; Amellal N; Hitt R
    N Engl J Med; 2008 Sep; 359(11):1116-27. PubMed ID: 18784101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
    Machiels JP; Schmitz S
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer.
    Blick SK; Scott LJ
    Drugs; 2007; 67(17):2585-607. PubMed ID: 18034592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma.
    Surmeli ZG; Ozveren A; Arslan C; Degirmenci M; Karaca B; Uslu R
    Indian J Cancer; 2019; 56(1):4-8. PubMed ID: 30950435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatment options for metastatic head and neck cancer.
    Price KA; Cohen EE
    Curr Treat Options Oncol; 2012 Mar; 13(1):35-46. PubMed ID: 22252884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.